Isoform selective phospholipase D inhibitors
    75.
    发明授权
    Isoform selective phospholipase D inhibitors 有权
    同型选择性磷脂酶D抑制剂

    公开(公告)号:US09127005B2

    公开(公告)日:2015-09-08

    申请号:US13386397

    申请日:2010-07-23

    IPC分类号: A61K31/438 C07D471/10

    CPC分类号: C07D471/10

    摘要: Disclosed are isoform selective Phospholipase D inhibitors. In one aspect, the disclosed compounds can have a structure represented by a formula (I): Also disclosed are methods of making and using the compounds. Also disclosed are pharmaceutical compositions and kits comprising the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

    摘要翻译: 公开了同工型选择性磷脂酶D抑制剂。 一方面,所公开的化合物可以具有由式(I)表示的结构:还公开了制备和使用该化合物的方法。 还公开了包含该化合物的药物组合物和试剂盒。 该摘要旨在作为用于在特定技术中进行搜索的扫描工具,而不意在限制本发明。

    Somatostatin Agonists
    78.
    发明申请
    Somatostatin Agonists 审中-公开
    生长抑素激动剂

    公开(公告)号:US20090258853A1

    公开(公告)日:2009-10-15

    申请号:US12225027

    申请日:2007-03-09

    摘要: This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof.

    摘要翻译: 本发明涉及作为生长抑素的激动剂并且对生长抑素受体亚型SSTR2有选择性的化合物。 该化合物可用于治疗和预防糖尿病以及糖尿病相关病理学,包括视网膜病变,神经病变和肾病。 许多化合物是口服活性的。 因此,本发明的目的是描述这些化合物。 进一步的目的是描述生长抑素激动剂的具体优选的立体异构体。 另一个目的是描述制备这些化合物的方法。 另一个目的是描述使用这些化合物作为其活性成分的方法和组合物。

    INDOLE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC RECEPTOR
    80.
    发明申请
    INDOLE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC RECEPTOR 失效
    作为MUSCARINIC受体的阳性调节因子的化合物

    公开(公告)号:US20130210773A1

    公开(公告)日:2013-08-15

    申请号:US13702800

    申请日:2011-06-21

    申请人: Craig W. Lindsley

    发明人: Craig W. Lindsley

    摘要: In one aspect, the invention relates to indole compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

    摘要翻译: 一方面,本发明涉及可用作毒蕈碱性乙酰胆碱受体M1(mAChR M1)的正变构调节剂的吲哚化合物,其衍生物和相关化合物。 制备化合物的合成方法; 包含该化合物的药物组合物; 以及使用该化合物和组合物治疗与毒蕈碱性乙酰胆碱受体功能障碍相关的神经和精神疾病的方法。 该摘要旨在作为用于在特定技术中进行搜索的扫描工具,而不意在限制本发明。